Method for determining preeclampsia risk
OwnerHamutal Meiri, Marei Sammar +1inventors
InventorsHamutal Meiri, Marei Sammar, Renate Hillermann
Life of this patent
Estimating the term…
Abstract
A method for determining the risk of a mother of a fetus to develop preeclampsia during pregnancy comprising: (a) providing a sample of genomic DNA from an individual related to the fetus; (b) analyzing the DNA for the presence of one or more mutations in the PP13 gene; and (c) determining the risk of the mother on the basis of the presence of the mutations. Also disclosed are mutated PP13 protein variants, and a kit for use in the method of the invention comprising DNA probes for specific genomic sequences of the PP13 native gene and/or mutated sequences thereof.
Claims29
A method for determining the risk of a mother of a fetus to develop preeclampsia during pregnancy comprising:
- (a) providing a sample of genomic DNA from an individual related to the fetus;
- (b) analyzing the DNA for the presence of one or more mutations in the PP13 gene;
- and
- (c) determining the risk of the mother on the basis of the presence of the mutations.
A method for determining the risk of a pregnant woman to develop preeclampsia comprising:
- (a) providing a sample of a PP13 molecule from a bodily substance of the mother;
- (b) determining the structure of the PP13 molecule;
- and
- (c) determining the risk of the woman on the basis of the structure of the PP13 molecule.
A mutated PP13 protein variant.
A method for purifying a mutated PP13 protein variant in soluble form comprising:
- (a) expressing the PP13 variant in a host cell;
- (b) disrupting the host cell and centrifuging the cell contents;
- (c) resuspending the centrifuged pellet in buffer containing a high concentration of a denaturation agent;
- (d) loading the resuspended pellet on an affinity column capable of binding PP13;
- (e) washing the affinity column with a gradient of the denaturation agent;
- and
- (f) eluting the PP13 in soluble form from the column.
A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA probes for specific genomic sequences of the PP.13 native gene and/or mutated sequences thereof.
A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising antibodies against the PP13 native sequence and/or mutated sequences thereof.
A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising RNA probes for specific sequences of the PP13 native mRNA and/or mutated sequences thereof.
A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA probes for specific sequences of the PP13 cDNA and/or mutated sequences thereof.
A kit for use in a method for determining the risk of a woman to develop preeclampsia comprising DNA or RNA chips comprising specific sequences of the PP13 cDNA or RNA and/or mutated sequences thereof.
Dependencies are inferred from the claim text.